50-76-0

50-76-0结构式
50-76-0结构式

化源商城直购

中文名 放线菌素D
英文名 actinomycin D
中文别名 硫化剂双-25
放线菌素C1
更生霉素
更生霉素D
英文别名 dactinomycin
2-Amino-N,N'-bis[(6S,9R,10S,13R,18aS)-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
noxazin-1,9-dicarboxamid
2-amino-4,6-diméthyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-triméthyl-6,13-bis(1-méthyléthyl)-1,4,7,11,14-pentaoxohexadécahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatétraazacyclohexadécin-10-yl]-3H-phé
Actinomycin AIV
2-Amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phe
3H-phenoxazine-1,9-dicarboxamide, 2-amino-N1,N9-bis[(6S,9R,10S,13R,18aS)-hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-
Actinomycin X1
2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide
EINECS 200-063-6
MFCD00070921
2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-di(propan-2-yl)hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide
MERACTINOMYCIN
Actinomycin I1
Acto-D
Actinomycin D
Chounghwamycin B
2-Amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazin-1,9-dicarboxamid
Dilactone actinomycin D acid
2-amino-4,6-diméthyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-triméthyl-6,13-bis(1-méthyléthyl)-1,4,7,11,14-pentaoxohexadécahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatétraazacyclohexadécin-10-yl]-3H-phénoxazine-1,9-dicarboxamide
3H-phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis[(6S,9R,10S,13R,18aS)-hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-
ACT
Oncostatin K
noxazine-1,9-dicarboxamide
3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N-bis[(6S,9R,10S,13R,18aS)-hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-
3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N-bis[(6S,9R,10S,13R,18aS)-hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohe
 xadecin-10-yl]-4,6-dimethyl-3-oxo-
描述 Actinomycin D 抑制 DNA 修复,IC50 为 0.42 μM。
相关类别
靶点

IC50: 0.42 μM (DNA repair)[1]

体外研究 放线菌素D是DNA转录和复制的抑制剂[1]。放线菌素D通过抑制80nM的BrdU掺入显着降低血管平滑肌细胞(SMC)的增殖。使用流式细胞分析进一步支持G1期阻滞。放线菌素D非常有效,抑制浓度IC50为0.4nM,而致死剂量LD50为260μM。增殖细胞核抗原(PCNA),粘着斑激酶(FAK)和Raf的蛋白表达水平均被放线菌素D抑制。细胞周期信号调节激酶(Erk)参与细胞周期停滞,发现放线菌素D增加[2]。
体内研究 将含有80nM和80μM放线菌素D的pluronic凝胶局部施用以包围大鼠颈动脉外膜,新内膜的厚度显着减少(分别为45%和55%)[2]。放线菌素D和氟达拉滨组中的小鼠比对照组寿命显着更长,P值分别<0.001和0.007。有趣的是,单用放线菌素D治疗总体生存率优于氟达拉滨(P = 0.026)[3]。
激酶实验 将放线菌素D在30℃下与含有以下物质的反应混合物共孵育3小时:120mg HeLa细胞的全细胞提取物,70mM KCl,dGTP,dCTP,dATP和地高辛化-dUTP各0.4mM。反应缓冲液含有40mM Hepes-KOH(pH 7.6),5mM MgCl 2,0.5mM二硫苏糖醇,2mM EGTA,10mM磷酸肌酸,50mg / mL磷酸肌酸和360mg / mL牛血清白蛋白。在该反应过程中,识别DNA损伤并且切除的贴片被新合成的DNA片段替换。在整个DNA合成中,掺入了地高辛化的dUMP。通过三次洗涤终止DNA修复反应[1]。
动物实验 小鼠[3]将原始Eμ-TCL1a转基因小鼠与C57BL / 6小鼠回交> 9代.C57BL / 6野生型小鼠植入来自Eμ-TCL-1转基因小鼠的肿瘤细胞。通过从尾静脉采血并通过流式细胞术分析,在小鼠中常规检查外周血中CD5 + / CD19 +细胞的百分比。当外周血中肿瘤细胞的百分比达到40-60%时,开始治疗。每天通过ip注射施用放线菌素D(0.06mg / kg,10天)。
参考文献

[1]. Barret JM, et al. Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplateassay. Carcinogenesis. 1997 Dec;18(12):2441-5.

[2]. Wu CH, et al. The molecular mechanism of actinomycin D in preventing neointimal formation in rat carotid arteries after balloon injury. J Biomed Sci. 2005;12(3):503-12.

[3]. Merkel O, et al. Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. Leukemia. 2012 Dec;26(12):2508-16.

密度 1.4±0.1 g/cm3
沸点 1386.0±65.0 °C at 760 mmHg
熔点 251-253 °C
分子式 C62H86N12O16
分子量 1255.417
闪点 792.1±34.3 °C
精确质量 1254.628418
PSA 359.98000
LogP -4.03
外观性状 红色结晶粉末
蒸汽压 0.0±0.3 mmHg at 25°C
折射率 1.656
储存条件

密封4℃干燥避光保存。

稳定性 Stable, but light sensitive, especially in dilute solution. Incompatible with strong acids, strong bases, strong oxidizing agents. Combustible.
水溶解性 SOLUBLE
计算化学

1、 疏水参数计算参考值(XlogP):3.8

2、 氢键供体数量:5

3、 氢键受体数量:18

4、 可旋转化学键数量:8

5、 互变异构体数量:64

6、 拓扑分子极性表面积(TPSA):356

7、 重原子数量:90

8、 表面电荷:0

9、 复杂度:3030

10、同位素原子数量:0

11、确定原子立构中心数量:0

12、不确定原子立构中心数量:10

13、确定化学键立构中心数量:0

14、不确定化学键立构中心数量:0

15、共价键单元数量:1

更多

1. 性状:鲜红色结晶性粉末,无臭,有吸湿性。遇光;热或氧化剂均能使其效价降低。

2. 密度(g/mL,25/4℃):未确定

3. 相对蒸汽密度(g/mL,空气=1):未确定

4. 熔点(ºC):251-253°C

5. 沸点(ºC,常压):未确定

6. 沸点(ºC, 5.2 kPa):未确定

7. 折射率:未确定

8. 闪点(ºC):未确定

9. 比旋光度(º):[α]18D-315°(0.02%,甲醇)

10. 自燃点或引燃温度(ºC):未确定

11. 蒸气压(kPa,25 ºC):未确定

12. 饱和蒸气压(kPa,60 ºC):未确定

13. 燃烧热(KJ/mol):未确定

14. 临界温度(ºC):未确定

15. 临界压力(KPa):未确定

16. 油水(辛醇/水)分配系数的对数值:未确定

17. 爆炸上限(%,V/V):未确定

18. 爆炸下限(%,V/V):未确定

19. 溶解性:未溶于石油醚,微溶于水,溶于甲醇、乙醇及乙酸乙酯,易溶于苯、氯仿和丙酮。

Name: Actinomycin D Material Safety Data Sheet
Synonym: Dactinomycin
CAS: 50-76-0
Section 1 - Chemical Product MSDS Name:Actinomycin D Material Safety Data Sheet
Synonym:Dactinomycin

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
50-76-0 Actinomycin D 100.0 200-063-6
Hazard Symbols: T+
Risk Phrases: 28

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Very toxic if swallowed.Light sensitive.
Potential Health Effects
Eye:
May cause severe eye irritation. May cause eye injury.
Skin:
May cause skin sensitization, an allergic reaction, which becomes evident upon re-exposure to this material.
Ingestion:
May be fatal if swallowed. May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
May cause respiratory tract irritation. May cause effects similar to those described for ingestion. Inhalation may produce coughing, nausea, and pulmonary edema.
Chronic:
Repeated exposure may cause sensitization dermatitis.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid if irritation develops or persists. Wash clothing before reuse. Flush skin with plenty of soap and water. Destroy contaminated shoes.
Ingestion:
Call a poison control center. If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid if cough or other symptoms appear. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Wash area with soap and water. Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Do not store in direct sunlight. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep refrigerated. (Store below 4C/39F.)

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Use only under a chemical fume hood.
Exposure Limits CAS# 50-76-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: red
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 245-252C
Autoignition Temperature: Not applicable.
Flash Point: 241 deg C ( 465.80 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: 250 deg C
Solubility in water: In methanol
Specific Gravity/Density:
Molecular Formula: C62H86N12O16
Molecular Weight: 1255.5

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, light, dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases, strong acids Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 50-76-0: AU1575000 LD50/LC50:
CAS# 50-76-0: Oral, mouse: LD50 = 13 mg/kg; Oral, mouse: LD50 = 20 mg/kg; Oral, rat: LD50 = 7200 ug/kg.
Carcinogenicity:
Actinomycin D - California: carcinogen, initial date 10/1/89 Other:
See actual entry in RTECS for complete information.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Products which are considered hazardous for supply are classified as Special Waste and the disposal of such chemicals is covered by regulations which may vary according to location. Contact a specialist disposal company or the local waste regulator for advice. Empty containers must be decontaminated before returning for recycling.

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: T+
Risk Phrases:
R 28 Very toxic if swallowed.
Safety Phrases:
S 1 Keep locked up.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 50-76-0: 3
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 50-76-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 50-76-0 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A
符号 GHS06
GHS06
信号词 Danger
危害声明 H300
警示性声明 P264-P301 + P310
个人防护装备 Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
危害码 (欧洲) T+:Verytoxic;
风险声明 (欧洲) R28;R40;R61
安全声明 (欧洲) S53-S36/37/39-S45-S1-S36/37-S28-S22
危险品运输编码 UN 3462 6.1/PG 2
WGK德国 3
RTECS号 AU1575000
包装等级 II
危险类别 6.1(a)
海关编码 29419000
上游产品  4

下游产品  0

该品是由放线菌产生的多肽抗生素。我国从桂林土壤中分离出Str. melanochromogehes菌株的发酵液中提取的产品称更生霉素,与国外报道的放线菌素D相同。

海关编码 29419000